{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06421935",
            "orgStudyIdInfo": {
                "id": "MS202659_0001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-513492-41-00",
                    "type": "OTHER",
                    "domain": "EU CTR"
                }
            ],
            "organization": {
                "fullName": "EMD Serono",
                "class": "INDUSTRY"
            },
            "briefTitle": "M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501)",
            "officialTitle": "An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 as a Single Agent and in Combination With the ATR Inhibitor Tuvusertib in Participants With Advanced Solid Tumors (DDRiver 501)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "as-single-agent-or-in-combination-with-tuvusertib-in-advanced-solid-tumors-ddriver"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-26",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-14",
            "studyFirstSubmitQcDate": "2024-05-14",
            "studyFirstPostDateStruct": {
                "date": "2024-05-20",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "EMD Serono Research & Development Institute, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck KGaA, Darmstadt, Germany",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 as monotherapy or in combination with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumor"
            ],
            "keywords": [
                "PARP inhibitor",
                "castration-resistant prostate cancer",
                "ovarian cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 70,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "M9466 plus Tuvusertib",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9466",
                        "Drug: Tuvusertib"
                    ]
                },
                {
                    "label": "M9466 Monotherapy",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: M9466"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "M9466",
                    "description": "Participants will be administered M9466 orally.",
                    "armGroupLabels": [
                        "M9466 Monotherapy",
                        "M9466 plus Tuvusertib"
                    ],
                    "otherNames": [
                        "HRS-1167;"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tuvusertib",
                    "description": "Participants will be administered Tuvusertib orally.",
                    "armGroupLabels": [
                        "M9466 plus Tuvusertib"
                    ],
                    "otherNames": [
                        "Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Module 1 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs",
                    "timeFrame": "Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)"
                },
                {
                    "measure": "Module 1 Part A1: Number of Participants with Dose Limiting Toxicity (DLT)-like events",
                    "timeFrame": "Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)"
                },
                {
                    "measure": "Module 2 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466",
                    "timeFrame": "Day 1, Day 8 and Day 15"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Module 1 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466 and Tuvusertib",
                    "timeFrame": "Day 1, Day 8 and Day 15"
                },
                {
                    "measure": "Module 1 Part A1: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 as Assessed by Investigator",
                    "timeFrame": "Time from first treatment to planned assessment at 12 months"
                },
                {
                    "measure": "Module 1 Part A1: Effect of M9466 in combination with tuvusertib on QTc interval as determined by Digital ECGs",
                    "timeFrame": "Time from first treatment to planned assessment at 12 months"
                },
                {
                    "measure": "Module 2 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-Related AEs",
                    "timeFrame": "Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)"
                },
                {
                    "measure": "Module 2 Part A1: Number of Participants with Abnormalities in Digital Electrocardiogram (ECG) Measures",
                    "timeFrame": "Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)"
                },
                {
                    "measure": "Module 2 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466 and Tuvusertib",
                    "timeFrame": "Day 1, Day 8 and Day 15"
                },
                {
                    "measure": "Module 2 Part A1: Relative Changes in Pharmacodynamic Markers In Paired Tumor Biopsies",
                    "timeFrame": "Day 1, Day 8 and Day 15"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Module 1 Part A1 and Module 2 Part A1: Locally advanced or metastatic disease that is refractory to standard therapy or for which no standard therapy is judged appropriate by the Investigator\n* Eastern Cooperative Oncology Group Performance Status less than or equal to (\\<=) 1\n* Life expectancy of more than 6 months\n* Have adequate hematologic function\n* Participants who received chemotherapy, extensive radiotherapy, biological therapy (e.g. antibodies) or investigational agents will have a washout period of 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives whichever is shorter, prior to starting study intervention with M9466 (\u00b1 tuvusertib)\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Persistence of Adverse Events related to any prior treatments that have not recovered to Grade less than 1 by NCI Common Terminology Criteria for Adverse Events- v5.0 unless AEs are clinically nonsignificant and/or stable on supportive therapy in the opinion of the Investigator (e.g. neuropathy or alopecia)\n* Participant has a history of malignancy within 5 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hypertropia, or malignancy that in the opinion of the Investigator, with concurrence of the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years)\n* Participants with known brain metastases, except if clinically controlled, which is defined as individuals with Central Nervous System (CNS) tumors that have been treated, are asymptomatic and who have discontinued steroids (for the treatment of CNS tumors) for more than 28 days\n* Serious Gastrointestinal bleeding within 3 months, refractory nausea and vomiting, uncontrolled diarrhea, known malabsorption, significant small bowel resection or gastric bypass surgery, use of feeding tubes, other chronic gastrointestinal disease (including exocrine pancreatic insufficiency requiring pancreatic enzyme replacement therapy), and/or other situations that may preclude adequate absorption of oral medications\n* Cerebrovascular accident or stroke\n* Other protocol defined exclusion criteria could apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US Medical Information",
                    "role": "CONTACT",
                    "phone": "888-275-7376",
                    "email": "eMediUSA@emdserono.com"
                },
                {
                    "name": "Communication Center",
                    "role": "CONTACT",
                    "phone": "+49 6151 72 5200",
                    "email": "service@emdgroup.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Responsible",
                    "affiliation": "EMD Serono Research & Development Institute, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Please Contact U.S. Medical Information",
                    "city": "Rockland",
                    "state": "Massachusetts",
                    "zip": "02370",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Please Contact U.S. Medical Information",
                            "role": "CONTACT",
                            "phone": "888-275-7376",
                            "email": "eMediUSA@emdserono.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.13066,
                        "lon": -70.91616
                    }
                },
                {
                    "facility": "Please Contact the Communication Center",
                    "city": "Darmstadt",
                    "zip": "64293",
                    "country": "Germany",
                    "contacts": [
                        {
                            "name": "Please Contact the Communication Center",
                            "role": "CONTACT",
                            "phone": "+49 6151 72 5200",
                            "email": "service@emdgroup.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 49.87167,
                        "lon": 8.65027
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Trial Awareness and Transparency website",
                    "url": "https://clinicaltrials.emdgroup.com/en"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M205",
                    "name": "Poly(ADP-ribose) Polymerase Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}